Wei Tang
Impact in
- Hepatology top 1%
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Research top 2%
- Cancer-related molecular mechanisms research
Papers in
-
- Glycosylation and Glycoproteins Research 13
- Oncology 36
- Peptidase Inhibition and Analysis 10
- Co-authors
- Yoshinori Inagaki (45 shared papers)Norihiro Kokudo (43 shared papers)Norihiro Kokudo (17 shared papers)Fanghua Qi (14 shared papers)Jianjun Gao (16 shared papers)Anyuan Li (6 shared papers)Peipei Song (23 shared papers)Yasuhiko Sugawara (27 shared papers)
- Journals
- BioScience Trends (30 papers)Drug Discoveries & Therapeutics (11 papers)Oncology Reports (5 papers)International Journal of Molecular Medicine (3 papers)Medicine (3 papers)
- Partner nations
- ChinaJapanUnited States
In The Last Decade
Wei Tang
175 papers receiving 4.6k citations
Peers
Comparison fields: 5 of 143
- Hepatology 713
- Cancer Research 691
- Toxicology 139
- Oncology 712
- Pharmacology 234
Countries citing papers authored by Wei Tang
This map shows the geographic impact of Wei Tang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wei Tang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wei Tang more than expected).
Fields of papers citing papers by Wei Tang
This network shows the impact of papers produced by Wei Tang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wei Tang. The network helps show where Wei Tang may publish in the future.
Co-authors
The 25 scholars most cited alongside Wei Tang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 178 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Chinese herbal medicines as adjuvant treatment during chemo- or radio-therapy for cancer. | 2010 | 292 |
| 2 | 2010 | 211 | |
| 3 | 2011 | 157 | |
| 4 | 2022 | 133 | |
| 5 | 2010 | 121 | |
| 6 | Traditional Chinese medicine and related active compounds against hepatitis B virus infection. | 2010 | 105 |
| 7 | 2010 | 102 | |
| 8 | 2012 | 101 | |
| 9 | 2013 | 90 | |
| 10 | 2015 | 89 | |
| 11 | 2009 | 85 | |
| 12 | 2016 | 84 | |
| 13 | 2020 | 74 | |
| 14 | 2006 | 74 | |
| 15 | 2016 | 73 | |
| 16 | 2008 | 62 | |
| 17 | 2018 | 61 | |
| 18 | 2016 | 61 | |
| 19 | 2011 | 60 | |
| 20 | 2010 | 57 |
About Wei Tang
Wei Tang is a scholar working on Molecular Biology, Oncology, Cancer Research, Hepatology and Epidemiology, having authored 178 papers that have together received 4.7k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (28 papers), Glycosylation and Glycoproteins Research (13 papers), Protease and Inhibitor Mechanisms (11 papers), Liver Disease Diagnosis and Treatment (10 papers), Peptidase Inhibition and Analysis (10 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (9 papers), Hepatitis B Virus Studies (7 papers) and Pharmacological Effects of Natural Compounds (7 papers). The work is most often cited by research in Hepatology (713 citations), Cancer Research (691 citations), Toxicology (139 citations), Oncology (712 citations) and Pharmacology (234 citations). Wei Tang has collaborated with scholars based in China, Japan and United States. Frequent co-authors include Yoshinori Inagaki, Norihiro Kokudo, Norihiro Kokudo, Fanghua Qi, Jianjun Gao, Anyuan Li, Peipei Song, Yasuhiko Sugawara, Munehiro Nakata and Kiyoshi Hasegawa. Their work appears in journals such as BioScience Trends, Drug Discoveries & Therapeutics, Oncology Reports, International Journal of Molecular Medicine and Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.